Arca
Skip to content

Hypercholesterolemia

Drug research and approvals for hypercholesterolemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 88 studies of hypercholesterolemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 49 drug trials for it since 2013, FDA has 12 approved and 12 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 88
  • Trials authorized in Canada: 49
  • FDA orphan approvals: 12
  • EU medicines: 6

Recruiting Now

Newest start dates first, of 88 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 49; search them all in Canada trials
Aug 7, 2026An operationally seamless phase 2/3 study to evaluate the safety, efficacy, and pharmacokinetics of enlicitide decanoate in pediatric participants with…ENLICITIDE (MK-0616)Merck & Co. (MSD)Pending
Jul 17, 2026A phase III randomised, double-blind, factorial design study to assess the effect of fixed dose combination laroprovstat/rosuvastatin compared with…LAROPROVSTAT / ROSUVASTATIN / LAROPROVSTAT-ROSUVASTATINAstraZeneca Pharmaceuticals LPOngoing
Jul 17, 2026A phase III randomised, double-blind, parallel-group study to assess the effect of fixed dose combination laroprovstat/rosuvastatin compared with rosuvastatin…ROSUVASTATIN / LAROPROVSTAT-ROSUVASTATINAstraZeneca Pharmaceuticals LPPending
Oct 8, 2025Phase 3 study to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (yosemite)ZODASIRAN (ARO-ANG3, ADS-004)ARROWHEAD PHARMACEUTICALS, INC.Ongoing
May 16, 2025A phase III, randomised, double-blind, placebo-controlled, parallel-group study to assess the effect of azd0780 on low-density lipoprotein cholesterol in…LAROPROVSTAT (AZD0780)AstraZeneca Pharmaceuticals LPOngoing
Jun 5, 2024A phase 3, randomized, double-blind study to evaluate the efficacy and safety of mk-0616 compared with ezetimibe or bempedoic acid or ezetimibe and bempedoic…MK-0616 / BEMPEDOIC ACID / EZETIMIBEMerck & Co. (MSD)Closed
Jun 3, 2024A phase 3, open-label extension study to evaluate the safety and efficacy of mk-0616 in adults with hypercholesterolemiaENLICITIDE DECANOATE (MK-0616)Merck & Co. (MSD)Ongoing
Feb 22, 2024Open-label, phase lb, single ascending dose study to evaluate the safety of verve-102 administered to patients with heterozygous familial hypercholesterolemia…VERVE-102VERVE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF ELI LILLY AND COMPANYOngoing
Jun 28, 2023A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mk¿0616 in adults with heterozygous familial…ENLICITIDE DECANOATE (MK-0616)Merck & Co. (MSD)Closed
Feb 10, 2023Safety and effectiveness of evinacumab for the treatment of homozygous familial hypercholesterolemia in a real life setting in canadaEVKEEZA (EVINACUMAB (REGN1500))ECOGENE-21Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 24
Feb 12, 2026Leqvioas an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in pediatric patients aged 12 years and older with…Novartis Pharmaceuticals CorporationApproved
Oct 9, 2025Praluentas an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in adults with homozygous familial…Regeneron Pharmaceuticals, Inc.Approved
Sep 25, 2025Evkeezaas an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and…Regeneron Pharmaceuticals, Inc.Approved
Aug 21, 2025Repathaas an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and…Amgen Inc.Approved
Mar 21, 2023Evkeezaas an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients,…Regeneron Pharmaceuticals, Inc.Approved
Sep 24, 2021RepathaAs an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and…Amgen Inc.Approved
Apr 1, 2021Praluentas an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-CRegeneron Pharmaceuticals, Inc.Approved
Feb 11, 2021Evkeezaadjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12…Regeneron Pharmaceuticals, Inc.Approved
May 27, 2016CrestorAn adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial…iPR Pharmaceuticals, Inc.Approved
Aug 27, 2015RepathaAs an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require…Amgen Inc.Approved
Jan 29, 2013KYNAMROAdjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total…Kastle Therapeutics, LLCApproved
Dec 21, 2012JuxtapidAdjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein…Chiesi Farmaceutici S.p.A.Approved
Sep 11, 2026messenger RNA encoding for adenine base editor protein and…treatment of homozygous familial hypercholesterolemiaVerve Therapeutics, a Wholly Owned Subs of Eli Lilly and CoDesignated
Aug 14, 2025recombinant adeno-associated virus serotype 8 vector…treatment of homozygous familial hypercholesterolemiaNGGT INC.Designated
May 15, 2025mRNA encoding the cholesterol degrading platform (CDP)…treatment of homozygous familial hypercholesterolemia (HoFH)Repair Biotechnologies, Inc.Designated

Medicines Authorised in the EU

Newest first
Jun 17, 2021EvkeezaevinacumabUltragenyx Germany GmbHEMA ↗
Dec 9, 2020LeqvioinclisiranNovartis Europharm LimitedEMA ↗
Apr 1, 2020Nilemdobempedoic acidDaiichi Sankyo Europe GmbHEMA ↗
Mar 27, 2020Nustendibempedoic acid;ezetimibeDaiichi Sankyo Europe GmbHEMA ↗
Jul 31, 2013LojuxtalomitapideChiesi Farmaceutici SpAEMA ↗
Mar 9, 2004CholestagelcolesevelamCHEPLAPHARM Arzneimittel GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.